U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06945523) titled 'CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer' on April 11.
Brief Summary: Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months.
CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expres...